TITLE

Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study

AUTHOR(S)
Guerra, Fiona M.; Rosella, Laura C.; Dunn, Sheila; Wilson, Sarah E.; Cynthia Chen; Deeks, Shelley L.
PUB. DATE
March 2016
SOURCE
BMJ Open;2016, Vol. 6 Issue 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
113834792

 

Related Articles

  • Human papillomavirus (HPV) infection in heterosexual South African men attending sexual health services: associations between HPV and HIV serostatus. Müller, Etienne E.; Chirwa, Tobias F.; Lewis, David A. // Sexually Transmitted Infections;Jun2010, Vol. 86 Issue 3, p7 

    Objectives To investigate the distribution of human papillomavirus (HPV) genotypes and determine the associations between HPV infection and HIV coinfection in sexually active heterosexual men with anogenital warts (GW), male urethral discharge or asymptomatic men. Methods Valid specimens for HPV...

  • Provinces weighing HPV vaccination of boys. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;3/20/2012, Vol. 184 Issue 5, pE250 

    The article focuses on the implementation of human papillomavirus (HPV) vaccination for boys by the National Advisory Committee on Immunization in Canada. It says that HPV vaccines will prevent anal intraepithelial neoplasia (AIN), cancer, and anogenital warts (AGWs). According to the committee,...

  • Prevalence of Anogenital Warts Among Participants in Private Health Plans in the United States, 2003-2010: Potential Impact of Human Papillomavirus Vaccination. Flagg, Elaine W.; Schwartz, Robert; Weinstock, Hillard // American Journal of Public Health;Aug2013, Vol. 103 Issue 8, p1428 

    Objectives. We estimated anogenital wart prevalence from 2003 to 2010 by gender and age group in a large US cohort with private insurance to detect potential decreases among people most likely to be affected by human papillomavirus (HPV) vaccination. Methods. We restricted health care claims to...

  • Human papillomavirus vaccine. Souter, Jacqui // South African Pharmaceutical Journal;2013, Vol. 80 Issue 1, p12 

    The article offers information regarding the availability of vaccines for the prevention of Human papillomavirus (HPV). It mentions that HPV infection cause genital cancers and anogenital warts. It highlights that the vaccines for HPV includes Gardasil® and Cervarix®. It further informs...

  • Genital Human Papillomavirus Infection. Dunne, Eileen F.; Markowitz, Lauri E. // Clinical Infectious Diseases;9/1/2006, Vol. 43 Issue 5, p624 

    Over the past few decades, epidemiology and natural history studies have led to improved understanding of human papillomavirus (HPV) infection and to promising prevention strategies. HPV infection is the cause of anogenital warts and cervical cancer, as well as a proportion of other anogenital...

  • HPV/cancer jab switch could save millions of pounds a year.  // Community Practitioner;Sep2011, Vol. 84 Issue 9, p7 

    The article discusses the study by Great Britain Health Protection Agency (HPA), which reveals that the National Health Service (NHS) of Great Britain could save cash if it replaced cervical cancer vaccines with the quadrivalent human papillomavirus (HPV) vaccine called Gardasil which also...

  • Human papillomaviruses vaccine: A dermatologic perspective. Satyaprakash, Anita K.; Tyring, Stephen K. // Indian Journal of Dermatology, Venereology & Leprology;Jan/Feb2010, Vol. 76 Issue 1, p14 

    Human papillomaviruses (HPV) are responsible for both benign anogenital warts and malignant disease in humans, especially cervical cancer. Dermatologists in India recognize a great many cases of anogenital warts, and affl icted individuals may be at increased risk of coinfection with oncogenic...

  • Human Papillomavirus Vaccines: the End of the Road for Cervical Cancer? Fiander, Alison N.; Tristram, Amanda J. // Current Medical Literature: Gynecology & Obstetrics;2007, Vol. 12 Issue 3, p61 

    The article offers information on human papillomavirus vaccines. Human papillomavirus virus (HPV) is a virus that infects squamous epithelial surfaces. Low-risks types of HPV cause anogenital warts while high-risk oncogenic types of HPV cause anogenital neoplasia. Neoplasia is found most often...

  • Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil): a guide to its use in the EU. Keating, Gillian; McCormack, Paul // Drugs & Therapy Perspectives;Jan2015, Vol. 31 Issue 1, p1 

    The quadrivalent human papillomavirus (HPV) [types 6, 11, 16, 18] recombinant vaccine (Gardasil) is approved in the EU for use from the age of 9 years for the prevention of premalignant anogenital lesions and cervical and anal cancers, and genital warts caused by the vaccine HPV types. In...

  • A quadrivalent vaccine against human papillomavirus prevented anogenital diseases in young women.  // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p71 

    The article focuses on a clinical study investigating the effectiveness of quadrivalent vaccine against human papillomavirus (HPV) in preventing anogenital diseases in young women. It discusses the selection criteria of the participants, follow up period, and the randomized controlled trials,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics